

SYNTHESIS OF (±)-JULANDINE AND (±)-CRYPTOPLEURINE

Hideo Iida and Chihiro Kibayashi


Tokyo College of Pharmacy, Horinouchi, Hachioji, Tokyo 192-03, Japan

Summary: An efficient synthesis of (±)-julandine and (±)-cryptopleurine has been achieved starting from the isoxazolidine formed via nitrene cycloaddition reaction.

Cryptopleurine (2), forming a rare group of alkaloids with the phenanthro[9,10-b]quinolizidine skeleton together with cryptopleuridine,¹ has been shown to possess unique and interesting biological properties² including vesicant and anticancer^{2b} activities. For this reason and to study structure-activity relationship, this alkaloid and its biogenetic congener, julandine (1), have recently received the intense attention, and three independent syntheses³⁻⁵ of cryptopleurine (2) based on biogenetic considerations have been reported.⁶ We now describe a new, efficient synthesis of (±)-julandine and (±)-cryptopleurine.

Our synthesis of the alkaloids 1 and 2 began with the preparation of the isoxazolidine 5 as a key intermediate which was attained by the 1,3-dipolar cycloaddition reaction of 2,3,4,5-tetrahydropyridine 1-oxide (3) with 3,4-dimethoxystyrene (4). The reaction performed in boiling toluene proceeded regioselectively to give the oily product in 93% yield (NMR (CDCl₃) δ 3.84 and 3.87 (s, 3H each), 4.94 (br m, 1H, OCHAr); MS m/e 263 (M⁺, base)). Reductive N-O bond fission of 5 with zinc in aqueous acetic acid (r.t., 2.5 h) gave the amino alcohol 6 in 90% yield (mp 148-149 °C; IR (CHCl₃) 3630-3150 cm⁻¹; NMR (CDCl₃) δ 3.85 and 3.87 (s, 3H each), 4.96 (br t, J = 6 Hz, ArCHOH), 6.81 (s, 2H), 6.92 (s, 1H)). Treatment of the amino alcohol 6 with p-methoxyphenylacetyl chloride in dichloromethane in the presence of K₂CO₃ (0 °C, 4 h) yielded a chromatographically separable mixture of the amido alcohol 7 (mp 134-135 °C; IR (CHCl₃) 3325, 1605 cm⁻¹; NMR (CDCl₃) δ 3.77, 3.84, and 3.87 (s, 3H each)) and the amido ester 8 (IR (CHCl₃) 1725, 1605 cm⁻¹), the latter of which, the minor product, was subsequently hydrolyzed (aqueous MeOH, K₂CO₃, reflux, 1 h) to produce 7 (total yield of 7: 64%). The amido alcohol 7 was then converted to the keto amide 9 (IR (CHCl₃) 1660, 1600 cm⁻¹; NMR (CDCl₃) δ 3.76 (s, 3H, OCH₃), 3.92 (s, 6H, 2 x OCH₃)) by Collins oxidation (CH₂Cl₂, r.t., 2 h) in 82% yield. Aldol condensation of the keto amide 9 was accomplished by treatment of sodium ethoxide in ethanol (reflux, 2 h), affording the lactam 10 (mp 142.5-143 °C (lit.³ 141-142 °C)) in 67% yield which was then converted to (±)-julandine (1) (mp 139-140 °C) with LiAlH₄ (THF-Et₂O, reflux, 1 h) in 63% yield. Synthetic (±)-julandine exhibited the identical spectra (IR, NMR) with those of a natural sample and was proved to be directly identical in all respects with an authentic synthetic specimen. On the other hand, upon irradiation of lactam 10 (high pressure Hg lamp, dioxane, I₂, r.t., 20 h), two fluorescent photocyclization products, 11 (mp 194-196 °C (lit.³ 194-195 °C)) and 12 (mp 155-156 °C; NMR (CDCl₃) δ 3.85, 3.95, and 4.03 (s, 3H each), 7.30 and 7.79 (AB q, J = 9 Hz, 2H), 7.22 (dd,

$J = 9$ and 3 Hz, $1H$), 9.17 (d, $J = 3$ Hz, $1H$), 9.32 (d, $J = 9$ Hz, $1H$) were obtained in 49 and 14% yields, respectively. The former product with the adequate methoxyl substitution mode on the ring A was finally led to (\pm)-cryptopleurine (**2**) (mp 201 – 202 °C (lit.⁴ 199 – 200 °C)) by reduction with $LiAlH_4$ in THF in 95% yield. The synthetic substance was found to be identical with natural ($-$)-cryptopleurine by comparison of TLC and NMR ($CDCl_3$) and IR ($CHCl_3$) spectra.



Acknowledgement: We are very grateful to Dr. J. A. Lambertson, CSIRO, for generously providing us with spectra of natural julandine and a sample of synthetic julandine, and also to Professor E. Gellert, The University of Wollongong, for natural cryptopleurine.

REFERENCES

- S. R. Johns, J. A. Lambertson, A. A. Sioumis, and R. I. Willing, *Aust. J. Chem.*, **23**, 353 (1970).
- a) I. S. de la Lamde, *Aust. J. Exp. Biol. Med. Sci.*, **26**, 181 (1948); E. J. Webb, *Aust. J. Sci.*, **11**, 26 (1948); H. Hofmann, *Aust. J. Exp. Biol. Med. Sci.*, **30**, 541 (1952); J. M. Haslam, P. J. Davey, A. W. Linnance, and M. R. Atkinson, *Biochem. Biophys. Res. Commun.*, **33**, 368 (1968); N. R. Farnsworth, N. K. Hart, S. R. Johns, J. A. Lambertson, and W. M. Messmer, *Aust. J. Chem.*, **22**, 1805 (1969); E. Krmpotic, N. R. Farnsworth, and W. M. Messmer, *J. Pharm. Sci.*, **61**, 1508 (1972).
b) E. Gellert and R. Rudzats, *J. Med. Chem.*, **7**, 361 (1964); G. R. Donaldson, M. R. Atkinson, and A. W. Murry, *Biochem. Biophys. Res. Commun.*, **31**, 104 (1968); J. L. Hartwell and B. J. Abbott, *Adv. Pharmacol. Chemother.*, **7**, 117 (1969).
- J. M. Paton, P. L. Pauson, and T. S. Stevens, *J. Chem. Soc. (C)*, 1309 (1969).
- E. Kotani, M. Kitazawa, and S. Tobinaga, *Tetrahedron*, **30**, 3027 (1974).
- R. B. Herbert, *J. Chem. Soc. Chem. Commun.*, 794 (1978).
- For alternate pioneering works for the synthesis of **2**, see C. K. Bradsher and H. Berger, *J. Am. Chem. Soc.*, **80**, 930 (1958); P. Marchini and B. Belleau, *Can. J. Chem.*, **36**, 581 (1958).